Corpus overview


Overview

MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

ProteinS (49)

ProteinN (10)

NSP5 (10)

ComplexRdRp (8)

ProteinE (7)


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 2071 - 2073 records in total 2073
    records per page




    Potent binding of 2019 novel coronavirus spike protein PROTEIN by a SARS coronavirus-specific human monoclonal antibody

    Authors: Xiaolong Tian; Cheng Li; Ailing Huang; Shuai Xia; Sicong Lu; Zhengli Shi; Lu Lu; Shibo Jiang; Zhenlin Yang; Yanling Wu; Tianlei Ying

    doi:10.1101/2020.01.28.923011 Date: 2020-01-28 Source: bioRxiv

    The newly identified 2019 novel coronavirus (2019-nCoV) has caused more than 800 laboratory-confirmed human infections, including 25 deaths MESHD, posing a serious threat to human health. Currently, however, there is no specific antiviral treatment or vaccine. Considering the relatively high identity of receptor binding domain (RBD) in 2019-nCoV and SARS-CoV MESHD, it is urgent to assess the cross-reactivity of anti-SARS-CoV antibodies with 2019-nCoV spike protein PROTEIN, which could have important implications for rapid development of vaccines and therapeutic antibodies against 2019-nCoV. Here, we report for the first time that a SARS-CoV-specific human monoclonal antibody, CR3022, could bind potently with 2019-nCoV RBD (KD of 6.3 nM). The epitope of CR3022 does not overlap with the ACE2 HGNC binding site within 2019-nCoV RBD. Therefore, CR3022 has the potential to be developed as candidate therapeutics, alone or in combination with other neutralizing antibodies, for the prevention and treatment of 2019-nCoV infection MESHDs. Interestingly, some of the most potent SARS-CoV-specific neutralizing antibodies (e.g., m396, CR3014) that target the ACE2 HGNC binding site of SARS-CoV MESHD failed to bind 2019-nCoV spike protein PROTEIN, indicating that the difference in the RBD of SARS-CoV MESHD and 2019-nCoV has a critical impact for the cross-reactivity of neutralizing antibodies, and that it is still necessary to develop novel monoclonal antibodies that could bind specifically to 2019-nCoV RBD.

    2019-20 Wuhan coronavirus outbreak: Intense surveillance is vital for preventing sustained transmission in new locations

    Authors: Robin Nicholas Thompson

    doi:10.1101/2020.01.24.919159 Date: 2020-01-25 Source: bioRxiv

    The outbreak of pneumonia MESHD originating in Wuhan, China, has generated 830 confirmed cases, including 26 deaths MESHD, as of 24 January 2020. The virus (2019-nCoV) has spread elsewhere in China and to other countries, including South Korea, Thailand, Japan and USA. Fortunately, there has not yet been evidence of sustained human-to-human transmission outside of China. Here we assess the risk of sustained transmission whenever the coronavirus arrives in other countries. Data describing the times from symptom onset to hospitalisation for 47 patients infected in the current outbreak are used to generate an estimate for the probability that an imported case is followed by sustained human-to-human transmission. Under the assumptions that the imported case is representative of the patients in China, and that the 2019-nCoV is similarly transmissible to the SARS coronavirus, the probability that an imported case is followed by sustained human-to-human transmission is 0.37. However, if the mean time from symptom onset to hospitalisation can be halved by intense surveillance, then the probability that an imported case leads to sustained transmission is only 0.005. This emphasises the importance of current surveillance efforts in countries around the world, to ensure that the ongoing outbreak will not become a large global epidemic.

    A Powerful Modelling Framework for Nowcasting and Forecasting COVID-19 MESHD and Other Diseases

    Authors: Oliver Stoner; Theo Economou; Alba Halliday

    id:1912.05965v2 Date: 2019-12-12 Source: arXiv

    The COVID-19 MESHD COVID-19 MESHD pandemic has highlighted delayed reporting as a significant impediment to effective disease surveillance and decision-making. In the absence of timely data, statistical models which account for delays can be adopted to nowcast and forecast cases or deaths MESHD. We discuss the four key sources of systematic and random variability in available data for COVID-19 MESHD and other diseases, and critically evaluate current state-of-the-art methods with respect to appropriately separating and capturing this variability. We present a general spatio-temporal hierarchical framework for correcting delayed reporting and demonstrate its application to daily English hospital deaths from COVID-19 MESHD and Severe Acute Respiratory Infection MESHD cases in Brazil. We compare our approach to competing models with respect to theoretical flexibility and quantitative metrics from a rolling nowcasting experiment imitating a realistic operational scenario. Based on consistent and compelling leads in nowcasting accuracy, bias, and precision, we demonstrate that our approach represents the current best-practice for correcting delayed reporting.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.